Looks like they want to do it themselves, or with a partner. From the filing
"Corporate Strategy – Clinical Development. Our team is poised to take this important medicine into the clinic for testing in both brain and breast cancer and in macular degeneration. Our current plan is to complete pre-clinical work for the filing of an Investigational New Drug Application (“IND”) in the ocular indication initially and conduct a Phase I/IIA clinical trial thereafter. If a partnership is obtained for eye disease drug development, those IND funds would be allocated to a cancer IND to be followed by Phase I/II clinical trials in patients with high risk of metastatic progression at MSKCC, under the supervision of Dr. Larry Norton, (Deputy Physician-in-Chief at MSKCC and Medical Director of the Evelyn H. Lauder Breast Center) the Head of the AngioGenex Scientific Advisory Board. With the initiation of these trials, designed to establish safety and proof of principle in humans, the Id story will have come full circle, from a basic biological finding in an academic lab to the discovery of an active chemical inhibitor to be tested on real patients in a clinic at the very institute where it all began. If we raise sufficient resources we would conduct both the oncology and ocular programs simultaneously.
The Path Forward. If we successfully complete safety and preliminary efficacy trials, we will seek further financing or a corporate partner for the completion of testing and the ultimate marketing of the drug. Our goal is to achieve interim milestones toward FDA approval in a number of disease indications with distinct proprietary pharmaceutical products."
News 
Market Data 
Discover 
